secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001493152-23-008712
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air appoints Jeff Myers, M.D., Ph.D. as Chief Medical Officer effective March 27, 2023
--------------------------------------------------------------------------------

- Dr. Myers brings ~15 years of biopharmaceutical executive experience and was previously a cardiothoracic surgeon at Massachusetts General Hospital.
- Incumbent CMO Dr. Andrew Colin transitions to Senior Medical Director Global Clinical Leadership.
- Dr. Myers received inducement option for 50,000 shares and inducement RSU for 50,000 shares, vesting over 4 and 5 years respectively.
- Stock awards were approved by independent compensation committee under Nasdaq Listing Rule 5635(c)(4).
- Beyond Air focuses on inhaled nitric oxide via LungFit platform for respiratory conditions and solid tumors through affiliate Beyond Cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223008712/0001493152-23-008712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223008712/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer